コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sedation, akathisia (for aripiprazole), and extrapyramidal symptoms.
2 dverse events at the injection site and more extrapyramidal symptoms.
3 performance and shows reduced liability for extrapyramidal symptoms.
4 toms without marked positive, depressive, or extrapyramidal symptoms.
5 oncentration correlated with the severity of extrapyramidal symptoms.
6 rates of dysphoria, depressive symptoms, and extrapyramidal symptoms.
7 t is clinically effective with a low risk of extrapyramidal symptoms.
8 mptoms of schizophrenia; quality of life; or extrapyramidal symptoms.
9 impson-Angus Rating Scale was used to assess extrapyramidal symptoms.
10 onventional antipsychotic agents in terms of extrapyramidal symptoms.
11 e apparently unrelated subjects with similar extrapyramidal symptoms.
12 events and the use of medications related to extrapyramidal symptoms.
13 e risperidone and olanzapine groups reported extrapyramidal symptoms (24% and 20%, respectively).
17 Safety and tolerability evaluations included extrapyramidal symptoms and effects on weight, prolactin
18 otic agents in producing significantly fewer extrapyramidal symptoms and having a lower risk of tardi
19 that has associated chronic cocaine use with extrapyramidal symptoms and striatal dopaminergic deplet
20 ated patients had a significant reduction in extrapyramidal symptoms and subjective measures of stiff
22 in the domains of symptoms, quality of life, extrapyramidal symptoms, and a synthetic measure of mult
23 ant even after lifetime medication exposure, extrapyramidal symptoms, and abnormal involuntary moveme
26 athy, clubfoot, absent deep tendon reflexes, extrapyramidal symptoms, and persistently deficient myel
29 ol-treated patients experienced worsening of extrapyramidal symptoms, as indicated by several measure
30 % of treated patients develop characteristic extrapyramidal symptoms caused by haloperidol-induced to
31 Safety was assessed using adverse events, Extrapyramidal Symptom (EPS) rating scales, laboratory v
32 or antipsychotic drugs which will not induce extrapyramidal symptoms (EPS) and tardive dyskinesias (T
33 ng there is a potential risk of exacerbating extrapyramidal symptoms (EPS) if H3R antagonists were us
34 regard to both the antipsychotic action and extrapyramidal symptoms (EPS) of antipsychotic drugs (AP
35 scular events, as well as metabolic effects, extrapyramidal symptoms, falls, cognitive worsening, car
36 th anti-NMDA receptor antibodies both showed extrapyramidal symptoms following initiation of treatmen
37 and is necessary to reduce the expression of extrapyramidal symptoms induced by chronic haloperidol t
38 safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalep
40 tolerated and associated with a low rate of extrapyramidal symptoms; neither weight gain nor clinica
41 H] = 87), stroke (NNH = 53 for risperidone), extrapyramidal symptoms (NNH = 10 for olanzapine; NNH =
43 es carrying a single parkin mutation without extrapyramidal symptoms or signs also had psychiatric sy
45 ignificant cognitive impairment, increase in extrapyramidal symptoms, or central anticholinergic effe
48 lactic benztropine) in compliance, symptoms, extrapyramidal symptoms, or overall quality of life, and
49 Although olanzapine is associated with fewer extrapyramidal symptoms, other side effects may offset t
50 rrected QT-interval prolongation (p = 0.16), extrapyramidal symptoms (p = 0.31), excessive sedation (
52 to explain the therapeutic efficacy and low extrapyramidal symptom profile of atypical antipsychotic
54 elated to 1) change in negative symptoms, 2) extrapyramidal symptom profile, 3) effect on prolactin l
64 ter TTR (SMD=-0.27) and a lower incidence of extrapyramidal symptoms (RR=0.31, NNH=7) compared with h
65 hisia Scale, and Modified Simpson-Angus [for Extrapyramidal Symptoms] Scale) and electromechanical as
66 ssessed by recording adverse events and with extrapyramidal symptom scales and electrocardiograms at
67 luded spontaneously reported adverse events, extrapyramidal symptom scores, serum prolactin concentra
70 iapine was well tolerated and did not induce extrapyramidal symptoms, sustained elevations of prolact
71 experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multipl
73 at improvement in positive, negative, and/or extrapyramidal symptoms was associated with mood improve
76 hereas the incidence of QTc prolongation and extrapyramidal symptoms was similar between groups, more
77 ebo group (p = .60), and a global measure of extrapyramidal symptoms was similar between treatment gr
82 owever, haloperidol carries a higher rate of extrapyramidal symptoms, whereas olanzapine is associate
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。